Glaxo Diabetes Drug Will Face SB's Avandia; Anti-Herpetic Divestment Likely
Executive Summary
Glaxo Wellcome intends to compete in the diabetes market with SmithKline Beecham's Avandia, Glaxo Chairman Richard Sykes indicated at an analysts earnings conference Feb. 16.
You may also be interested in...
Glaxo Advair "Approvable" At FDA; Flovent Tops $1 Bil. In 1999
Glaxo Wellcome will respond to an FDA "approvable" letter for the asthma product Advair Diskus by Feb. 18, Chairman Richard Sykes indicated during a Feb. 16 analysts conference.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011